Nurix Therapeutics (NASDAQ:NRIX) Announces Quarterly Earnings Results

Nurix Therapeutics (NASDAQ:NRIX) announced its quarterly earnings results on Wednesday. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.02, FiscalAI reports. The firm had revenue of $13.58 million for the quarter, compared to analyst estimates of $13.41 million. Nurix Therapeutics had a negative return on equity of 60.99% and a negative net margin of 314.90%.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX opened at $17.59 on Friday. The firm’s fifty day moving average is $18.50 and its two-hundred day moving average is $13.34. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -5.79 and a beta of 1.93. Nurix Therapeutics has a one year low of $8.18 and a one year high of $22.50.

Key Headlines Impacting Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Analyst upgrade: Royal Bank of Canada raised its price target to $30 and assigned an “outperform” rating, implying substantial upside vs current levels. Benzinga
• Positive Sentiment: Analyst confirmations: BTIG reaffirmed a “buy” rating with a $30 target, and Needham reaffirmed a “buy” with a $26 target — both signal continued analyst confidence in share appreciation. Benzinga
• Positive Sentiment: Clinical & corporate update: Nurix began dosing first patients in the DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL, presented supportive Phase 1 data at ASH 2025 (reported 83% ORR and 22.1?month PFS), disclosed differentiated preclinical data for IRAK4 degrader GS?6791 with Gilead, and ended the quarter with ~$592.9M in cash and marketable securities — items that materially improve execution and runway prospects. Corporate Update
• Neutral Sentiment: Quarterly results were mixed: NRIX reported a $0.82 loss per share, slightly better than consensus (-$0.86) and revenue of $13.58M vs. ~$13.41M expected — a modest beat on the headline numbers, but the company remains unprofitable with large negative margins. Press Release
• Negative Sentiment: Conflicting coverage: Zacks ran a headline framing the quarter as a loss that “misses revenue estimates,” which may create investor confusion despite the company-reported slight revenue beat — such mixed messaging can pressure the stock near earnings. Zacks

Wall Street Analyst Weigh In

Several analysts have recently commented on NRIX shares. Morgan Stanley set a $36.00 price objective on Nurix Therapeutics and gave the company an “overweight” rating in a report on Thursday, January 8th. Oppenheimer decreased their price target on Nurix Therapeutics from $30.00 to $28.00 and set an “outperform” rating for the company in a research note on Friday, October 10th. BTIG Research restated a “buy” rating and set a $30.00 price target on shares of Nurix Therapeutics in a research note on Thursday. Needham & Company LLC restated a “buy” rating and set a $26.00 price objective on shares of Nurix Therapeutics in a report on Thursday. Finally, Mizuho lifted their target price on shares of Nurix Therapeutics from $24.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

Insider Activity at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 6,284 shares of Nurix Therapeutics stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $12.56, for a total transaction of $78,927.04. Following the completion of the transaction, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at $472,155.52. The trade was a 14.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Nurix Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. purchased a new position in Nurix Therapeutics in the 3rd quarter valued at $405,000. Wexford Capital LP acquired a new stake in shares of Nurix Therapeutics in the third quarter valued at about $41,000. Velan Capital Investment Management LP lifted its stake in shares of Nurix Therapeutics by 60.0% in the third quarter. Velan Capital Investment Management LP now owns 16,000 shares of the company’s stock worth $148,000 after buying an additional 6,000 shares in the last quarter. Vestal Point Capital LP boosted its position in Nurix Therapeutics by 73.8% during the third quarter. Vestal Point Capital LP now owns 3,475,000 shares of the company’s stock worth $32,109,000 after acquiring an additional 1,475,000 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC purchased a new stake in Nurix Therapeutics during the 3rd quarter valued at about $100,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.